[89Zr]Panitumumab

N/A

Report date: 2025/09/09 15:00:16

Base Information

Drug Name[89Zr]Panitumumab
Drug Alias NameN/A
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody diagnosticsRadiation-emitting products > Radioactive diagnostic agent +[5] 
Mechanisms of ActionEpidermal growth factor receptor erbB1 antagonists
TargetsEpidermal growth factor receptor erbB1
Therapy Area/IndicationsPancreatic NeoplasmsColonic NeoplasmsSquamous Cell Carcinoma of Head and Neck
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesUniversity Of Alabama At BirminghamStanford UniversityVanderbilt-Ingram Cancer Center
China Registration ClassN/A

Develop Information

Active CompaniesVanderbilt-Ingram Cancer CenterUniversity Of Alabama At Birmingham
Inactive CompaniesStanford University
Active IndicationsSquamous Cell Carcinoma of Head and Neck
Inactive IndicationsPancreatic NeoplasmsColonic Neoplasms

Other Information

ATC CodeN/A
Related LinksN/A